Amphastar Pharma

Amphastar Pharmaceuticals, Inc. engages in developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, and insulin active pharmaceutical ingredient. It operates through Finished Pharmaceutical Products and Active Pharmaceutical Ingredients Products segments. The Finished Pharmaceutical Products segment manufactures, markets, and distributes Primatene Mist, enoxaparin, naloxone, phytonadione, lidocaine, and other critical and non-critical care drugs. The Active Pharmaceutical Ingredients Products segment offers RHI API and porcine insulin API for external customers and internal product development. The company was founded by Zi-Ping Luo and Yong Feng Zhang on February 29, 1996 and is headquartered in Rancho Cucamonga, CA.

Earnings data Q3 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Should You Invest in Amphastar (AMPH) Based on Bullish Wall Street Views?

RANCHO CUCAMONGA, CA / ACCESSWIRE / September 13, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar") today announced the pricing of $300.0 million aggregate principal amount of 2.00% convertible senior notes due 2029 (the "notes") in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Amphastar also granted the initial purchasers of the notes an option to purchase up to an additional $45.0 million aggregate principal amount of the notes.

Amphastar Pharmaceuticals Announces Pricing of Offering of $300.0 Million of Convertible Senior Notes

RANCHO CUCAMONGA, CA / ACCESSWIRE / September 11, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar") today announced that it intends to offer, subject to market conditions and other factors, $300.0 million aggregate principal amount of convertible senior notes due 2029 (the "notes") in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Amphastar also intends to grant the initial purchasers of the notes an option to purchase up to an additional $45.0 million aggregate principal amount of the notes.

Amphastar Pharmaceuticals Announces Proposed Private Offering of $300.0 Million of Convertible Senior Notes

Horizon Pharma

Disc Medicine Inc

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

The top five biotech stocks today have several commonalities. Among them are strong ratings.

The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks

RANCHO CUCAMONGA, CA / ACCESSWIRE / August 31, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will participate in an Analyst-Moderated fireside chat at the Wells Fargo Healthcare Conference on September 7, 2023 at 12:45 pm Eastern Time. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com.

Amphastar Pharmaceuticals to Present at the Wells Fargo Healthcare Conference

Amphastar Pharma (AMPH) shares are up 89.1% year to date due to the acquisition of Baqsimi from Lilly. The company also receives FDA approval for Naloxone.

Amphastar Pharma (AMPH) Stock Skyrockets 89% YTD: Here's Why

Amphastar (AMPH) could produce exceptional returns because of its solid growth attributes.

Is Amphastar (AMPH) a Solid Growth Stock? 3 Reasons to Think "Yes"

Dr. Reddy's Labs

Teva Pharmaceutical

The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry is gradually improving. New product launches provide some respite to AMPH, RDY and TEVA.

3 Generic Drug Stocks to Watch Amid Improving Market Prospects

Here is how Amphastar Pharmaceuticals (AMPH) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.

Is Amphastar Pharmaceuticals (AMPH) Stock Outpacing Its Medical Peers This Year?

Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.65 per share, beating the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.39 per share a year ago.

Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Beat Estimates

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH ) Q2 2023 Earnings Conference Call August 8, 2023 5:00 PM ET Company Participants Dan Dischner - Senior Vice President of Corporate Communications Bill Peters - Chief Financial Officer & Executive Vice President, Finance Tony Marrs - Executive Vice President, Regulatory Affairs & Clinical Operations Conference Call Participants Tim Chiang - Capital One David Amsellem - Piper Sandler Operator Greetings and welcome to the Amphastar Pharmaceuticals Second Quarter Earnings Call. At this time, all participants are in a listen-only mode.

Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2023 Earnings Call Transcript

Reports Net Revenues of $145.7 Million for the Three Months Ended June 30, 2023 RANCHO CUCAMONGA, CA / ACCESSWIRE / August 8, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended June 30, 2023. Second Quarter Highlights Net revenues of $145.7 million for the second quarter GAAP net income of $26.1 million, or $0.49 per share, for the second quarter Adjusted non-GAAP net income of $34.8 million, or $0.65 per share, for the second quarter Dr. Jack Zhang, Amphastar's President and Chief Executive Officer, commented: "We are pleased with the second quarter's results, which are partially attributable to glucagon and phytonadione delivering strong sales growth along with sales from newer products such as regadenoson, ganirelix and vasopressin adding another layer of strength.

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2023

RANCHO CUCAMONGA, CA / ACCESSWIRE / August 2, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its second quarter of 2023 ended June 30, 2023, after the market closes on Tuesday, August 8, 2023, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.

Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 8, 2023

Does Amphastar Pharmaceuticals (AMPH) have what it takes to be a top stock pick for momentum investors? Let's find out.

Amphastar Pharmaceuticals (AMPH) is a Great Momentum Stock: Should You Buy?

Abercrombie & Fitch

InterDigital

PGT Innovations

Shake Shack

We have narrowed our search to five mid-cap stocks with more than 50% returns year to date. These are: PGTI, SHAK, IDCC, ANF, AMPH.

5 Must-Buy High-Flying Mid-Caps to Enhance Your Portfolio

Amphastar (AMPH) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Amphastar (AMPH) is an Incredible Growth Stock: 3 Reasons Why

Amphastar Pharmaceuticals' share price has risen 54% in the last 12 months, outperforming the healthcare sector, due to its diversified revenues and recent acquisition of BAQSIMI from Eli Lilly and Company. The company's net margins have improved significantly, reaching a record 17.9%, and its EPS has grown each year for the last five years, making it an appealing growth opportunity for investors. Despite potential short-term cash flow pressures due to the cost of the BAQSIMI acquisition, the long-term outlook for Amphastar is strong.

Amphastar Pharma: A Company Growing Quickly As Acquisitions Likely Fuel Growth

Pinduoduo Inc - ADR

Suzano S.A. - ADR

PDD Holdings (PDD), Amphastar Pharmaceuticals (AMPH) and Suzano (SUZ) are some of the top picks with a high net income ratio.

3 Profitable Stocks Worth Investing in Using Net Income Ratio

Amphastar Pharmaceuticals (AMPH) Is Up 0.54% in One Week: What You Should Know

RANCHO CUCAMONGA, CA / ACCESSWIRE / June 30, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today announced that it has completed the previously announced acquisition of BAQSIMI® from Eli Lilly and Company ("Lilly") (the "Acquisition"). Acquisition Highlights Provides Amphastar with a branded product with growing sales and strong gross margin.

Amphastar Pharmaceuticals Completes Acquisition of BAQSIMI from Lilly

Amphastar Pharmaceuticals Inc. NASDAQ: AMPH, a small cap that's one of the leading performers within the biotech space, is forming an orderly pullback and is currently actionable as it holds above its 10-day moving average.

Promising Small Biotech Amphastar Sees Actionable Pullback

3 Reasons Growth Investors Will Love Amphastar (AMPH)

Here is how Amphastar Pharmaceuticals (AMPH) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Amphastar Pharmaceuticals (AMPH) This Year?

Axon Enterprise

Tecnoglass

PDD Holdings Inc. (PDD), Tecnoglass (TGLS), Amphastar Pharmaceuticals (AMPH) and Axon Enterprise (AXON) have been selected as the top picks with a high net income ratio.

4 Top-Ranked Profitable Stocks to Buy Using Net Income Ratio

Amphastar (AMPH) possesses solid growth attributes, which could help it handily outperform the market.

News for Amphastar Pharma Stock (AMPH)